Renovarocube to acquire 100% ownership of cyclomics, reinforcing cutting-edge cancer diagnostics partnership

Los angeles and amsterdam, april 24, 2024 (globe newswire) -- renovaro inc. (nasdaq: renb), a trailblazer in ai-driven early cancer diagnostics and therapeutics, and cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. renovarocube has entered into an amendment to its binding letter of intent to acquire 100% ownership of cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. their combined relationships with oxford nanopore and nvidia will further position renovarocube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. oxford nanopore is a leader in sequencing technologies and nvidia will provide vital super computing power and front edge software solutions such as parabricks, bionemo, monai and nemo.
RENB Ratings Summary
RENB Quant Ranking